Elizabeth Jungman directs Pew’s work on public health, overseeing initiatives related to antibiotics and innovation, drug safety, and prescription drug abuse.
Before joining Pew, she served as a senior health policy adviser with the U.S. Senate Committee on Health, Education, Labor, and Pensions, where she played a key role in drafting and negotiating the Food and Drug Administration Safety and Innovation Act of 2012, the FDA provisions in the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013, and the Drug Quality and Security Act of 2013, which included drug compounding and supply chain security measures.
Before moving to the Hill, Jungman was in private legal practice, counseling clients on a broad range of FDA regulatory matters and other health care issues related to the human pharmaceutical industry. She serves on FDA’s Pharmacy Compounding Advisory Committee and represents Pew as a member of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria. She has an undergraduate biology degree from Harvard College, a Juris Doctor from Georgetown University, and a master’s degree in public health from Johns Hopkins University.
Recent WorkView All
The Pew Charitable Trusts offered comments on draft guidance documents issued by the Food and Drug Administration in July 2016 regarding compounded drugs that are essentially copies of commercially available or approved drugs. The proposed guidance would preserve the FDA’s approval process, which is critical to protecting patient safety, while allowing important exceptions under limited,... Read More
Pharmacists often make drugs for patients whose clinical needs cannot be met by a commercially available product, a practice known as compounding. But should pharmacists compound drugs to reduce costs for patients and the health care system? Read More
The U.S. Food and Drug Administration (FDA) issued three draft guidance documents in April on implementation of the Drug Quality and Security Act (DQSA), a 2013 law governing the production of compounded drugs—medications made by pharmacies instead of drug manufacturers. Read More